Quick Summary
Albizia julibrissin is a traditional medicinal plant widely used in Chinese medicine. Scientific evidence regarding its clinical efficacy and safety in humans is limited and mainly preliminary. Most clinical research involves herbal formulations containing Albizia alongside other herbs, or studies situated within traditional Chinese medicine practice. Some studies suggest possible sedative, hypnotic, and neuroendocrine modulating effects, but robust clinical evidence focused specifically on Albizia is lacking.
What is it?
Albizia julibrissin, commonly known as silk tree or mimosa, is a deciduous tree native to Asia. Its flowers, bark, and other parts have been employed in traditional Chinese medicine for centuries. The plant is noted for its use in formulations intended to support emotional well-being and sleep.
Traditional Uses
Traditionally, Albizia has been used in Chinese medicine to soothe the spirit, promote relaxation, and aid sleep. It has also been utilized for its calming effects on mood and to modulate emotional disturbances.
Active Compounds
Key active compounds identified in Albizia include flavonoids such as quercetin found in the flower extracts (Flos Albiziae). These constituents are believed to contribute to its sedative and neuroactive properties through modulation of neurotransmitter systems.
Potential Benefits with Evidence Levels
- Sedation and sleep disorders (insomnia): Limited human clinical evidence. Animal studies demonstrated that aqueous extracts of Albizia flowers and quercetin may enhance hypnotic effects via the serotonergic system. A traditional herbal decoction containing Albizia showed sedative and hypnotic effects in insomnia animal models. No large randomized human trials specifically investigating Albizia monotherapy were found.
- Depressive symptoms and neuroendocrine modulation: Low to moderate level clinical evidence in Chinese herbal medicine formulations including Albizia or related herbs. Systematic reviews of multi-herb Chinese medicine adjuncts to antipsychotics or antidepressants reported improved depressive symptoms and neuroendocrine markers such as serotonin and brain-derived neurotrophic factor. However, effects cannot be attributed to Albizia alone.
Side Effects
Available data do not report significant adverse effects specifically linked to Albizia julibrissin. Mild and reversible adverse effects have been noted in some multi-herb preparations that include Albizia, but attribution to Albizia specifically is unclear. Overall, traditional use suggests Albizia is generally well tolerated when used appropriately.
Drug Interactions
No specific evidence regarding drug interactions with Albizia julibrissin was identified. Caution is advised when combining herbal products with pharmaceuticals due to potential unknown interactions.
Who Should Avoid It?
Given limited safety data, individuals with allergies to Albizia or related plants, those with underlying medical conditions requiring close supervision, and pregnant or breastfeeding women should avoid use or consult a healthcare professional before use.
Evidence Limitations
- Most clinical evidence involves multi-component herbal formulations rather than Albizia monotherapy, limiting conclusions about its specific effects.
- The majority of clinical studies originate from traditional Chinese medicine settings, with variable methodological quality and limited blinding.
- Animal and preclinical studies offer mechanistic insights but lack direct applicability to humans.
- Potential hepatotoxicity or other adverse effects specifically related to Albizia have not been systematically studied.
- No large-scale, high-quality randomized controlled trials focusing on Albizia julibrissin alone were identified.
References
- Ye MF et al. (2015). Flos Albiziae aqueous extract and its active constituent quercetin potentiate the hypnotic effect of pentobarbital via the serotonergic system. Europe PMC.
- Yang Y et al. (2021). Nyctinastic herbs decoction improves para-chlorophenylalanine-induced insomnia by regulating the expression level of neurotransmitters. Europe PMC.
- Kwon CY et al. (2026). Effectiveness of herbal medicine as an add-on to antipsychotics in patients with schizophrenia spectrum disorders accompanied by depression: A systematic review and meta-analysis. Europe PMC.
- Seung HB et al. (2023). Neuroendocrine Biomarkers of Herbal Medicine for Major Depressive Disorder: A Systematic Review and Meta-Analysis. Europe PMC.
- Teschke R et al. (2016). Traditional Chinese medicine (TCM) and herbal hepatotoxicity: RUCAM and the role of novel diagnostic biomarkers such as microRNAs. Europe PMC.
- Dobrek L, Głowacka K. (2023). Depression and Its Phytopharmacotherapy – A Narrative Review. Europe PMC.
- Cheng CY et al. (2024). Chinese herbal medicine treatment for benign thyroid nodules: Literature review. Europe PMC.
Last Reviewed
April 2024
Disclaimer: This information is intended for educational purposes only and should not be used as a substitute for professional medical advice. Consult a healthcare provider before using any herbal products, especially if you are pregnant, breastfeeding, have any medical conditions, or are taking medications.